SCHEMBL13035855

SCHEMBL13035855

CCOc1ccc(C(NC(C)=O)c2ccc(OC)cc2OC)cc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.72
▸ RAB9A P51151 3/20 0.54
▸ NPC1 O15118 2/20 0.54
▸ HTT P42858 2/20 0.54
▸ L3MBTL1 Q9Y468 2/20 0.54
▸ KDM4E B2RXH2 1/20 0.54
▸ MITF O75030 1/20 0.54
▸ TP53 P04637 1/20 0.54
▸ SMN1; SMN2 Q16637 1/20 0.54
▸ ACACB O00763 5/20 0.50
▸ ACACA Q13085 1/20 0.49
▸ TSHR P16473 2/20 0.48
▸ MAPT P10636 1/20 0.48
▸ MAPK1 P28482 1/20 0.48
▸ ALDH1A1 P00352 3/20 0.47
▸ KMT2A Q03164 6/20 0.46
▸ MEN1 O00255 3/20 0.46
▸ HIF1A Q16665 1/20 0.46
▸ POLB P06746 1/20 0.45
▸ NPSR1 Q6W5P4 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13034922 0.88 LMNA (0.56) LMNARAB9ANPC1HTTL3MBTL1
SCHEMBL16307735 0.88 LMNA (0.65) LMNARAB9ANPC1L3MBTL1ACACB
SCHEMBL13298385 0.85 LMNA (0.53) LMNARAB9ANPC1HTTL3MBTL1
SCHEMBL13635155 0.83 LMNA (0.52) LMNARAB9ANPC1HTTL3MBTL1
SCHEMBL13635158 0.83 LMNA (0.52) LMNARAB9ANPC1HTTL3MBTL1
SCHEMBL14205323 0.81 LMNA (0.49) LMNAKDM4EACACBTSHRMAPT
SCHEMBL14381016 0.81 LMNA (0.50) LMNAHTTSMN1; SMN2TSHRMAPT
SCHEMBL13635154 0.80 LMNA (0.47) LMNARAB9ANPC1HTTL3MBTL1
SCHEMBL16234064 0.80 LMNA (0.48) LMNARAB9ANPC1HTTL3MBTL1
SCHEMBL12873284 0.78 LMNA (0.46) LMNAKDM4ETP53ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8759295-B2 Peptide-peptidase inhibitor conjugates and methods of using same AMYLIN PHARMACEUTICALS, LLC (US) 2014-06-24 — — US disclosed
US-20100292172-A1 Peptide-Peptidase Inhibitor Conjugates and Methods of Using Same AMYLIN PHARMACEUTICALS, INC. (US) 2010-11-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292172-A1 Peptide-Peptidase Inhibitor Conjugates and Methods of Using Same DNPEP, PEPD, VIP LMNA 2488/4885RAB9A 1838/4885NPC1 669/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback